



CNS RESEARCH, INC.

12 Years of Excellence

DUNS # 13-461-2691

Fed ID# 05-0495163

FWA # 00014360

ACRP

Association of Clinical
Research Professionals

Alzheimer's disease Clinical Trials Experience

Protocol AVA102675- REFLECT 4

An open label extension study of the long term safety and efficacy of rosiglitazone extended release tablets (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild to moderate Alzheimer's Disease.

Protocol AVA102670

A 54 week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer's Disease.

E2020-G000-326

Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer's Disease.

CL – 758007 Phase III Study of the Efficacy and Safety of Alzhemed in Patients with Mild to Moderate Alzheimer's Disease.

ONO-2506

A Double-blind, Phase II, safety and efficacy evaluation of ONO-2506 in patients with mild to moderate Alzheimer's Disease

Exelon (rivastigmine)

A Prospective, 26-Week, Open-label, Single-arm, Multicenter Study Evaluating the Efficacy and Safety of Exelon (rivastigmine tartrate) in Patients with Mild to Moderate Alzheimer's Disease Who Are Responding Poorly to Aricept (donepezil) Treatment

GAL-INT-26

Johnson & Johnson PRD, GAL-INT-26, A randomized, double-blind, placebo-controlled trial to evaluate the safety & efficacy of galantamine in the treatment of dementia secondary to cerebrovascular disease.

GAL-USA-10

Janssen Research Foundation: GAL-USA-10, A double-blind, placebo-controlled multicenter study of safety and efficacy in Alzheimer's disease.

METRIFONATE

BAYER Corporation: A 26 week multicenter, open label comparison of METRIFONATE to standard therapy in patients with Alzheimer's disease.

MILAMELINE

PARKE-DAVIS: A 26 week, randomized, double-blind, parallel -group, placebo-controlled, multicenter study of MILAMELINE in patients with Alzheimer's disease.

SELEGILINE

SOMERSET PHARMACEUTICALS: A 12 month, double-blind, placebo-controlled, investigation of the safety and efficacy of SELEGILINE Transdermal System in patients with dementias of the Alzheimer's type.

MENTANE

HOECHST PHARMACEUTICALS: A double-blind, multicenter comparison of MENTANE and placebo in outpatients with Alzheimer's disease.

Norman M. Gordon, MD
Medical Director
Norman@cns-research.com
Tel. 1-800-707-6013
Fax 1-800-847-4332

Peter J. Bellafiore, MD
Principal Investigator
Annette@cns-research.com
Annette M. Phillips, RN
Research Coordinator

Elaine C. Jones, MD
Principal Investigator
Elaine@cns-research.com
Melissa Jenkins, PhD
Neuropsychologist

Fred Griffith, MD
Principal Investigator
Axel@cns-research.com
Axel J. Epple, MBA
Business Manager

Patricia Epple, RN, CCRC
Research Director
Patricia@cns-research.com
www.cns-research.com
info@cns-research.com